title: High-intensity chemotherapy with peripheral blood progenitor cell support.
abstract: In a series of clinical studies at Memorial Sloan-Kettering Cancer Center, we have used hematopoietic growth factors and peripheral blood-derived hematopoietic progenitor cells to facilitate delivery of multiple courses of high-dose chemotherapy at abbreviated treatment intervals. In these studies, we have demonstrated the feasibility of cross-over regimens involving induction chemotherapy with high-dose cyclophosphamide, supported by granulocyte colony-stimulating factor and followed by multiple peripheral blood leukapheresis to harvest progenitor cells. These cells are then used as rescue for the consolidation component of treatment, which, in the earlier-generation studies, consisted of a single course of high-dose carboplatin/etoposide/cyclophosphamide chemotherapy. In subsequent studies, patients received either four courses of high-dose carboplatin or carboplatin/cyclophosphamide or tandem courses of thiotepa. In all cases, the planned interval between treatments was 14 days, and the achieved median was approximately 16 days. These studies show that the administration of high-intensity regimens that deliver multiple courses of very high-dose chemotherapy at relatively brief intervals is feasible. Our current research focuses on exploiting these findings to devise disease-specific regimens for breast and ovarian cancer.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: D
authors.initials: D
authors.lastname: Fennelly
authors.forename: L
authors.initials: L
authors.lastname: Vahdat
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: L
authors.initials: L
authors.lastname: Reich
authors.forename: N
authors.initials: N
authors.lastname: Hamilton
authors.forename: T
authors.initials: T
authors.lastname: Hakes
authors.forename: G
authors.initials: G
authors.lastname: Raptis
authors.forename: C
authors.initials: C
authors.lastname: Wasserheit
authors.forename: A
authors.initials: A
authors.lastname: Kritz
authors.forename: S
authors.initials: S
authors.lastname: Gulati
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D013852:Thiotepa / Q000627:therapeutic use; D014182:Transplantation, Autologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013852:Thiotepa